Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label pediatric study of Lokelma for hyperkalaemia
2023-508455-38-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Sep 2019
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 12
01
Overview
Phase 3, open-label, single-arm trial of sodium zirconium cyclosilicate in hyperkalemia, sponsored by AstraZeneca. Primary endpoints: Correction phase primary endpoint and 28-day maintenance phase primary endpoint. Planned start Sep 2019; status: authorised.
02
Drugs
sodium zirconium cyclosilicate
03
Conditions
hyperkalemia
Beyond the preview
Go deeper on 2023-508455-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508455-38-00.